We are proud to present the BioCanRx 2023-24 Annual Report. While this year held uncertainties and more than a few questions, we continued to build on our strong foundation, completing research projects, collaborating with our network, and training the next generation of cancer immunotherapy researchers. This year also saw persistent growth in our commitment to patient-focused care, centering the patient voice and supporting positive patient experience within care networks alongside cutting-edge scientific discoveries.
With new funding from the Strategic Science Fund, we look forward to our future, as we continue to expand Canada’s immunotherapy network, improving patient experiences and outcomes, and pushing towards a time when all cancers are curable diseases.
Read the 2023-2024 Annual Report.
